Esperion Therapeutics Inc (ESPR) Stake Reduced by Martingale Asset Management L P

Martingale Asset Management L P reduced its position in shares of Esperion Therapeutics Inc (NASDAQ:ESPR) by 50.1% during the first quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 25,304 shares of the biopharmaceutical company’s stock after selling 25,407 shares during the period. Martingale Asset Management L P’s holdings in Esperion Therapeutics were worth $894,000 at the end of the most recent quarter.

A number of other institutional investors have also recently bought and sold shares of ESPR. Keybank National Association OH purchased a new position in Esperion Therapeutics during the fourth quarter worth $159,000. C WorldWide Group Holding A S purchased a new position in Esperion Therapeutics during the first quarter worth $162,000. Elkfork Partners LLC purchased a new position in Esperion Therapeutics during the fourth quarter worth $169,000. Princeton Alpha Management LP purchased a new position in Esperion Therapeutics during the first quarter worth $205,000. Finally, Bank of Montreal Can boosted its position in Esperion Therapeutics by 1,006.7% in the first quarter. Bank of Montreal Can now owns 6,596 shares of the biopharmaceutical company’s stock worth $233,000 after buying an additional 6,000 shares during the last quarter. 64.65% of the stock is owned by institutional investors.

Institutional Ownership by Quarter for Esperion Therapeutics (NASDAQ:ESPR)

Esperion Therapeutics Inc (ESPR) opened at 36.16 on Thursday. Esperion Therapeutics Inc has a 12 month low of $9.40 and a 12 month high of $48.21. The company’s market cap is $816.85 million. The stock’s 50 day moving average is $35.32 and its 200 day moving average is $25.02.

Esperion Therapeutics (NASDAQ:ESPR) last announced its earnings results on Monday, May 1st. The biopharmaceutical company reported ($1.80) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($1.44) by $0.36. During the same period in the prior year, the company earned ($0.65) EPS. Equities analysts predict that Esperion Therapeutics Inc will post ($6.69) earnings per share for the current year.

WARNING: This news story was published by Mideast Time and is the sole property of of Mideast Time. If you are reading this news story on another site, it was stolen and republished in violation of US and international trademark and copyright law. The legal version of this news story can be viewed at https://www.mideasttime.com/esperion-therapeutics-inc-espr-stake-reduced-by-martingale-asset-management-l-p/1762466.html.

ESPR has been the subject of a number of analyst reports. Citigroup Inc upped their price objective on shares of Esperion Therapeutics to $77.00 in a research report on Tuesday, March 21st. JPMorgan Chase & Co. upped their price objective on shares of Esperion Therapeutics from $22.00 to $50.00 in a research report on Tuesday, March 21st. Needham & Company LLC set a $25.00 price objective on shares of Esperion Therapeutics and gave the company a “buy” rating in a research report on Saturday, March 18th. Royal Bank of Canada reissued a “hold” rating and issued a $45.00 price objective on shares of Esperion Therapeutics in a research report on Monday, March 20th. Finally, Zacks Investment Research raised shares of Esperion Therapeutics from a “sell” rating to a “hold” rating in a research report on Thursday, March 2nd. Eight research analysts have rated the stock with a hold rating, five have given a buy rating and one has issued a strong buy rating to the stock. Esperion Therapeutics currently has an average rating of “Buy” and an average target price of $33.39.

In related news, Director Gilbert S. Omenn bought 1,000 shares of the company’s stock in a transaction on Tuesday, March 21st. The stock was bought at an average cost of $42.26 per share, with a total value of $42,260.00. Following the completion of the purchase, the director now owns 10,000 shares in the company, valued at approximately $422,600. The acquisition was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, Director Dov A. Md Goldstein sold 800,000 shares of the business’s stock in a transaction dated Wednesday, March 22nd. The stock was sold at an average price of $41.66, for a total transaction of $33,328,000.00. The disclosure for this sale can be found here. Insiders own 35.40% of the company’s stock.

Esperion Therapeutics Company Profile

Esperion Therapeutics, Inc is a lipid management company. The Company is a late-stage pharmaceutical company focused on developing and commercializing once-daily, oral therapies for the treatment of patients with elevated low-density lipoprotein cholesterol (LDL-C). With a targeted mechanism of action, bempedoic acid, the Company’s lead product candidate, is an orally available, once-daily adenosine triphosphate (ATP)-citrate lyase (ACL) inhibitor that reduces cholesterol biosynthesis and lowers elevated levels of LDL-C by up-regulating the LDL receptor, but with reduced potential for muscle-related side effects.new TradingView.widget({ “height”: 400, “width”: 625, “symbol”: “NASDAQ:ESPR”, “interval”: “D”, “timezone”: “Etc/UTC”, “theme”: “White”, “style”: “1”, “locale”: “en”, “toolbar_bg”: “#f1f3f6”, “enable_publishing”: false, “hideideas”: true, “referral_id”: “2588”});

Want to see what other hedge funds are holding ESPR? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Esperion Therapeutics Inc (NASDAQ:ESPR).

Receive News & Ratings for Esperion Therapeutics Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Esperion Therapeutics Inc and related companies with MarketBeat.com's FREE daily email newsletter.



Leave a Reply

 
© 2006-2017 Mideast Time.